Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Monday reported a loss of $119 million ...
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial ...
Zacks Investment Research on MSN
Recursion's Q3 earnings beat estimates on Sanofi milestone revenues
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...
In a Nov. 1 blog post, software engineer Nicolas Chagnet argues that Gleam pairs a simple functional syntax with the Erlang ...
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
A new study develops and compares two semi-analytical methods for solving nonlinear time-fractional reaction–diffusion ...
Altitude Lab will relocate its accelerator and startup community to Portal Innovations at Woodbine Labs, combining Utah's established biotech accelerator with new laboratory infrastructure, graduate ...
PhaSER Biomedical has a two-year, $2.7m Gates Foundation grant to give global health researchers access to its humanised 8HUM ...
Recursion announced new positive Phase 2 data from the ongoing TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor for familial adenomatous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results